Branded generics are generic versions of items supplied by either the original producer of the patented drug or generic manufacturers who have built up brand equity for their generic versions of the medication, which they present shortly after the original product’s patent expires. Branded generics are distinct from commodity generics, which are pharmaceutical drugs that are commonly utilised as a replacement for innovator products once their patents expire. The global branded generics market is expected to increase slowly throughout the projection period of 2014 to 2025, since a substantial number of pharmaceutical items will become off-patent.
Mergers and acquisitions by the top market players is likely to boost the growth of the market in forecast timeframe. For example. Lupin, a leading pharmaceutical industry announced the acquisitions of Australia based Southern Cross Pharma Ltd in 2021.
The Cardiovascular Diseases segment is projected as the fastest-growing segment in the Branded Generics Market. Cardiovascular diseases (CVDs) and diabetes continue to be the most popular therapeutic application categories, accounting for more than half of all branded generics sales worldwide. Cardiovascular disease (CVD) accounted for the largest market share in 2019, owing to high prevalence. According to the World Health Organization (WHO), 17.9 million people worldwide die each year as a result of cardiovascular illnesses (CVDs). Similarly, hypertension affects 1.13 billion people worldwide. This encourages the use of branded generics, such as anti-hypertensive medicines, which widens the market. The growing geriatric population, unhealthy lifestyles, and the availability of multiple novel medications in clinical trials are all factors driving the cardiovascular disease drug industry forward.
According to the India Brand Equity Foundation, India’s pharmaceutical business supplies over 50% of global demand for various vaccines, 40% of generic demand in the United States, and 25% of all pharmaceuticals in the United Kingdom. Branded generics dominate India’s pharmaceutical sector, resulting in generic-induced price competition. The rapid expansion of the branded generics market in India can also be ascribed to expanding disposable income, growing demand for branded generics at affordable rates, and rising chronic illness prevalence.
Despite a huge decline in the sales of Therapeutic Applications during the initial phase of pandemic spread and lockdown restrictions all over the region, the market is observed to pick up a quick pace for registering a CAGR of almost more than 5.2%, during the tenure of 2021 – 2027. The report published by Maximize encompasses the market dynamics, which could affect the market growth of Branded Generic in the region, the Value – Chain Analysis, and the PORTER’s analysis for the Branded Generic market at a global level
The study is associated based on major segments and further into sub-segments By Formulation Type (Oral, parenteral, Topical, Other), Therapeutic Application (Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics and Anti-inflammatory, Others), By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Others), by Distribution Channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies)
Lastly, the market research report provides a regional comparison and a complete country-level analysis for the Product trends, along with the major key players- Teva Pharmaceutical Industries Ltd, Mylan N.V., Hospira Inc., Dr. Reddy’s Laboratories Ltd., Apotex Inc., GlaxoSmithKline Pharmaceuticals Limited, Valeant, ZydusCadila, Sandoz, Lupin Pharmaceuticals, Inc. Par Pharmaceutical Companies, Inc., Sanofi, and AstraZeneca.
You can browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on the “Global Branded Generics Market.”
https://www.maximizemarketresearch.com/market-report/global-branded-generics-market/120963/
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051,
Maharashtra, India.
+91 9607195908